Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Notifies Prefectures of RMP Submissions for Generics
August 29, 2014
- New Chuikyo Rep Abe Credits Key Premium for Accelerating Drug Development
August 29, 2014
- MHLW Notifies Health Professionals of Revised Package Insert for Simeprevir
August 28, 2014
- Chuikyo Grants Unprecedented 60% Premium to Ono’s Opdivo
August 28, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- PFSB’s FY2015 Budget Request Seeks Funding to Increase PMDA Staff by 13 to Strengthen Its Consultation System
August 27, 2014
- MHLW’s FY2015 Budget Request at Record 31.67 Trillion Yen, Includes 74.8 Billion Yen to Promote Commercialization of Innovative New Drugs
August 27, 2014
- PAFSC Second Committee to Review Nobelpharma’s Anticancer Drug Streptozocin on Sept. 5
August 26, 2014
- MHLW to Promote Joint Drug Development by Pharmas, Academia
August 26, 2014
- PAFSC’s First Committee to Discuss Lixiana’s Additional Use on Sept. 4
August 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 11 - August 22
August 25, 2014
- PMDA Reviewing Lyrica for Risk of Fulminant Hepatitis, Hepatic Dysfunction
August 25, 2014
- Eisai Sues FDA over Shortened Exclusivity Time for Belviq, Fycompa
August 22, 2014
- MHLW Plans to Build Clinical Trial/Clinical Research Network with Centralized Disease-Based Patient Registry: FY2015 Preliminary Budget Request
August 22, 2014
- Report of Changes to Package Inserts to Be Required Before Providing Revised Information to Healthcare Professionals Under New System
August 21, 2014
- Health Sciences Council to Include “Program to Promote Joint Drug Development by Govt and Private Sector” in FY2015 Budget Request
August 21, 2014
- Generic Use Promotion Best Possible Way for Reducing Social Welfare Expenses: LDP Kono
August 20, 2014
- MHLW Drug Evaluation Head Eyes Flexible Designation Criteria for New Fast-Track Review System
August 19, 2014
- Emergency Use of Favipiravir to Be Permitted if Domestic Outbreak of Ebola Occurs: Health Minister
August 19, 2014
- 148 Blopress Generics OKed, Competition with AGs Likely upon December Listing
August 15, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…